Compare BridgeBio Pharma Inc (BBIO) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs First Trust Cloud Computing ETF — how do they compare? BridgeBio Pharma Inc trades at $82.09 (market cap $16.46B), while First Trust Cloud Computing ETF trades at $136.3. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, First Trust Cloud Computing ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | SKYY | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | — |
52-Week High | $90.17 | $155.17 |
52-Week Low | $44.81 | $104.16 |
Enterprise Value | $18.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
SKYY (First Trust Cloud Computing ETF) trades at $139.99 with a slight 0.16% daily gain, showing bullish technical momentum with strong moving average support. The ETF benefits from ongoing technology sector inflows and enterprise cloud adoption trends. Recent news highlights continued institutional interest in cloud computing ETFs as hyperscalers pivot to AI-first platforms.
The outlook remains positive given strong technical indicators and sector tailwinds, though investors should monitor potential overbought conditions. Key risks include technology sector volatility and competitive ETF offerings. Analyst coverage suggests sustained interest in cloud computing exposure amid digital transformation acceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
